Evidence map›Paper›PMID 37513350›Full record

ArticleMolecules (Basel, Switzerland)2023

[1,2,4]triazolo[4,3-

Cindy Patinote, Sandy Raevens, Amélie Baumann, Eloise Pellegrin, Pierre-Antoine Bonnet, Carine Deleuze-Masquéfa

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Synthesis and Biological Activity of Azolo[Molecules (Basel, Switzerland) · 2026
    Review
  2. Review
  3. NovelMolecules (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cindy PatinoteInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, (CNRS, ENSCM, Université de Montpellier), 1919 Route de Mende, 34090 Montpellier, France.ORCID 0000-0002-5854-310X
Sandy RaevensInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, (CNRS, ENSCM, Université de Montpellier), 1919 Route de Mende, 34090 Montpellier, France.
Amélie BaumannInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, (CNRS, ENSCM, Université de Montpellier), 1919 Route de Mende, 34090 Montpellier, France.
Eloise PellegrinInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, (CNRS, ENSCM, Université de Montpellier), 1919 Route de Mende, 34090 Montpellier, France.
Pierre-Antoine BonnetInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, (CNRS, ENSCM, Université de Montpellier), 1919 Route de Mende, 34090 Montpellier, France.ORCID 0000-0001-8579-4150
Carine Deleuze-MasquéfaInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, (CNRS, ENSCM, Université de Montpellier), 1919 Route de Mende, 34090 Montpellier, France.ORCID 0000-0002-4086-5178
École Nationale Supérieure de Chimie de Montpellier · FR

Funding

Ligue Nationale Contre le Cancer 6FI15159WJVJ
6 · The paper itself

Abstract

Cutaneous melanoma is one of the most aggressive human cancers and is the deadliest form of skin cancer, essentially due to metastases. Novel therapies are always required, since cutaneous melanoma develop resistance to oncogenic pathway inhibition treatment. The Imiqualine family is composed of heterocycles diversely substituted around imidazo[1,2-

Indexed as

Antineoplastic AgentsMelanomaSkin NeoplasmsCell LineCutaneous Malignant MelanomaHumansMolecular StructureQuinoxalinesStructure-Activity RelationshipAntineoplastic AgentsQuinoxalines[1,2,4]triazolo[4,3-a]quinoxalineA375 melanoma cell lineanticancer agentscytotoxic activitiesEAPB02303Imiqualinespharmacophore

Identifiers

PMID37513350
PMCPMC10384284
OpenAlexW4384823024

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.